ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015.
Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment.
Jan 30, 2013
Pfizer and Eli Lilly Report Strong Performance; Drug Pipelines Continue to Advance
Let's take a look at Pfizer's and Lilly's fourth-quarter reports.
Jan 2, 2013
Fiscal Cliff Averted; Aerospace Rallying
EDAC, Astronics, and Precision Castparts -- three of our favorite companies in aerospace -- are surging!
Dec 20, 2012
You Are Ahead of the News As a Valuentum Member
Remember how optimistic we were about economic growth when others were so bearish...did you see the GDP number today? Remember when we warned that President Obama and House Speaker Boehner are still far apart from a deal, despite all of the optimism. Did you see today that the White House will veto Boehner's "Plan B" bill?
Dec 18, 2012
Inside the New Abbott: A Lot Like the Old Abbott But Without Humira
We take a dive inside the prospects of the “new” Abbott, which is quite a bit like the old Abbott—minus Humira.
Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie.
Dec 5, 2012
FAQ: How Is Your Best Ideas Portfolio Doing This Year?
We answer a question that has come up a lot recently.
Oct 31, 2012
5 Highly Ranked Dividend Growth Stocks
Let's take a look at 5 highly ranked dividend growth stocks.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.